116 related articles for article (PubMed ID: 6088828)
1. Improvement of cardiac performance by AR-L 115 BS, a new cardiotonic drug, in the experimental failing dog heart.
Morita T; Satoh K; Taira N
Jpn Heart J; 1984 May; 25(3):439-45. PubMed ID: 6088828
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the cardiovascular and biochemical profiles of a new positive inotropic drug, AR-L 115 BS, with those of theophylline.
Morita T; Satoh K; Taira N
Jpn Heart J; 1984 May; 25(3):447-60. PubMed ID: 6088829
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of heart failure by MDL 17043 and MDL 19205, novel positive inotropic drugs, in dog heart-lung preparations.
Goto T; Nunoki K; Satoh K; Taira N
Jpn Heart J; 1985 Nov; 26(6):1011-8. PubMed ID: 2937939
[TBL] [Abstract][Full Text] [Related]
4. Improvement by trapidil of cardiac function of the dog heart-lung preparation depressed by pentobarbital.
Satoh K; Kawada M; Taira N
Jpn Heart J; 1983 May; 24(3):399-405. PubMed ID: 6876384
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular properties of a new cardiotonic agent, MDL 19205.
Dage RC; Roebel LE; Hsieh CP; Woodward JK
J Cardiovasc Pharmacol; 1984; 6(1):35-42. PubMed ID: 6199609
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of sulmazole (AR-L 115 BS) on contractile force and cyclic AMP levels in canine ventricular muscle: comparison with MDL 17,043.
Endoh M; Yanagisawa T; Morita T; Taira N
J Pharmacol Exp Ther; 1985 Jul; 234(1):267-73. PubMed ID: 2989507
[TBL] [Abstract][Full Text] [Related]
7. Improvement of pentobarbital-induced heart failure by MCI-154, a novel and potent cardiotonic agent, in the dog heart-lung preparation.
Satoh K; Nunoki K; Goto T; Hosono M; Hashimoto H; Sato Y; Taira N
Jpn J Pharmacol; 1988 Jun; 47(2):189-95. PubMed ID: 3199595
[TBL] [Abstract][Full Text] [Related]
8. Improvement of cardiac performance by pimobendan, a new cardiotonic drug, in the experimental failing dog heart.
Satoh K; Satoh Y; Imagawa J; Taira N
Jpn Heart J; 1993 Mar; 34(2):213-9. PubMed ID: 8315818
[TBL] [Abstract][Full Text] [Related]
9. The improvement of cardiac performance by amrinone, a new cardiotonic drug, in an experimental failing heart preparation of the dog.
Satoh K; Maruyama M; Taira N
Jpn Heart J; 1982 Nov; 23(6):975-80. PubMed ID: 7161881
[No Abstract] [Full Text] [Related]
10. Effects of AR-L 115 BS, a new cardiotonic compound, on cardiac contractility, heart rate and blood pressure in anaesthetized and conscious animals.
Diederen W; Kadatz R
Arzneimittelforschung; 1981; 31(1a):146-50. PubMed ID: 7195208
[TBL] [Abstract][Full Text] [Related]
11. [The effect of AR-L 115 BS on contractility dynamics of the isolated, metabolically supported dog heart (author's transl)].
Hockerts T; Höcht B; Broll R; Trenkel K; Sieber J; Kilian A; Brendle B
Arzneimittelforschung; 1981; 31(1a):157-61. PubMed ID: 7195211
[TBL] [Abstract][Full Text] [Related]
12. The acute effect of a new positive inotropic agent (AR-L 115 BS) on cardiac hemodynamics and contractility in patients with severe chronic congestive heart failure.
Hauf GF; Bubenheimer P; Roskamm H
Arzneimittelforschung; 1981; 31(1a):253-6. PubMed ID: 7195235
[TBL] [Abstract][Full Text] [Related]
13. Effects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failure.
Adachi H; Tanaka H
J Cardiovasc Pharmacol; 1997 Jun; 29(6):763-71. PubMed ID: 9234657
[TBL] [Abstract][Full Text] [Related]
14. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005.
Dundore RL; Pagani ED; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
J Cardiovasc Pharmacol; 1995 Jan; 25(1):14-21. PubMed ID: 7723343
[TBL] [Abstract][Full Text] [Related]
15. [Effect of Chinese-made vesnarinone on experimental heart failure of dog].
Du J; Yang Z
Hua Xi Yi Ke Da Xue Xue Bao; 1992 Jun; 23(2):178-80. PubMed ID: 1452153
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of AR-L115 BS in conscious dogs with and without chronic congestive heart failure.
Pouleur H; Rousseau MF; van Mechelen H; Roncoroni L; Ries A; Charlier AA
J Cardiovasc Pharmacol; 1982; 4(3):409-18. PubMed ID: 6177937
[TBL] [Abstract][Full Text] [Related]
17. [The effect of the benzimidazole derivative AR-L 115 BS on the activities of myocardial adenylate cyclase and phosphodiesterase preparations (author's transl)].
Schuhmacher P; Greeff K; Noack E
Arzneimittelforschung; 1982; 32(1):80-2. PubMed ID: 6277343
[TBL] [Abstract][Full Text] [Related]
18. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153
[TBL] [Abstract][Full Text] [Related]
19. Increase in calcium sensitivity of cardiac myofibrils contributes to the cardiotonic action of sulmazole.
van Meel JC; Zimmermann R; Diederen W; Erdman E; Mrwa U
Biochem Pharmacol; 1988 Jan; 37(2):213-20. PubMed ID: 2829914
[TBL] [Abstract][Full Text] [Related]
20. Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals.
Alousi AA; Canter JM; Montenaro MJ; Fort DJ; Ferrari RA
J Cardiovasc Pharmacol; 1983; 5(5):792-803. PubMed ID: 6195467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
